Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.

[1]  S. Rosenberg,et al.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.

[2]  S. Rosenberg,et al.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. , 1995, Journal of immunology.

[3]  L. Fabry,et al.  Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines , 1994, Journal of virology.

[4]  V. Hirsch,et al.  Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells , 1994, Journal of medical primatology.

[5]  B. Moss,et al.  A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. , 1994, Vaccine.

[6]  N. Haigwood,et al.  Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection , 1993, Journal of virology.

[7]  R. Desrosiers,et al.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. , 1992, Science.

[8]  B. Moss,et al.  Nonreplicating vaccinia vector efficiently expresses recombinant genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  N. Haigwood,et al.  Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. , 1992, AIDS research and human retroviruses.

[10]  M. Perkus,et al.  NYVAC: a highly attenuated strain of vaccinia virus. , 1992, Virology.

[11]  E. Paoletti,et al.  Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. , 1992, Virology.

[12]  P. Johnson,et al.  Genetic variation of simian immunodeficiency viruses in nonhuman primates. , 1992, AIDS research and human retroviruses.

[13]  G. Barber,et al.  Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. , 1992, Science.

[14]  B. Moss,et al.  Vaccinia virus: a tool for research and vaccine development , 1991, Science.

[15]  G. Sutter,et al.  Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. , 1991, The Journal of general virology.

[16]  P. Greenberg,et al.  Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein , 1991, The Lancet.

[17]  Jonathan A. Cooper,et al.  Deletion of the vaccinia virus growth factor gene reduces virus virulence , 1988, Journal of virology.

[18]  F. Fenner.  Smallpox and its eradication , 1988 .

[19]  B. Moss,et al.  Prevention of vaccinia virus infection in imiminodeficient mice by vector-directed IL-2 expression , 1987, Nature.

[20]  B. Coupar,et al.  Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection , 1987, Nature.

[21]  B. Coupar,et al.  Cell-mediated immune responses to influenza virus antigens expressed by vaccinia virus recombinants. , 1986, Microbial pathogenesis.

[22]  B. Moss,et al.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques , 1985, Molecular and cellular biology.

[23]  B. Moss,et al.  Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Moss,et al.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype , 1985, Nature.

[25]  B. Moss,et al.  Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells , 1984, Nature.

[26]  B. Moss,et al.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes , 1984, Journal of virology.

[27]  B. Moss,et al.  Vaccinia virus: a selectable eukaryotic cloning and expression vector. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Paoletti,et al.  Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Schäfer,et al.  MVA-Stufenimpfung gegen Pocken , 1974 .

[30]  A. Mayr,et al.  [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. , 1974, Deutsche medizinische Wochenschrift.